Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,306.00
Bid: 12,304.00
Ask: 12,308.00
Change: 188.00 (1.55%)
Spread: 4.00 (0.033%)
Open: 12,244.00
High: 12,314.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sterling steadies against dollar; Brexit talks extended to Wednesday

Mon, 26th Oct 2020 09:47

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv

LONDON, Oct 26 (Reuters) - Sterling stabilised against the
dollar on Monday as markets turned cautious over new lockdown
restrictions in Europe and record-high daily virus cases in the
United States, with riskier currencies losing out.

U.S. COVID-19 cases hit record highs over the weekend, with
hospitalisations at a two-month high. In Europe, Spain announced
a new state of emergency and Italy imposed new lockdown measures
to curb a second wave of infections.

Equities fell and the safe-haven dollar rose as a wave of
risk-aversion swept markets. The euro was down around 0.5%
against the dollar.

At 0935 GMT, the pound was flat against the dollar at
$1.3043. It was up around 0.4% against the euro, at
90.54 pence.

Brexit negotiations remain in focus for pound traders, as
the United Kingdom and the European Union have just over two
months left to agree on their future trading relationship, ahead
of a Dec. 31 deadline.

The EU's chief negotiator, Michel Barnier, has extended his
stay in London for intense Brexit trade talks until Oct. 28 -
news which had limited impact on sterling.

"News that UK-EU trade talks have been extended until 28
October ushers in a little more optimism that some kind of free
trade deal can be secured," wrote ING FX strategists in a note.

"Given the UK's economic underperformance, however,
prompting more Bank of England quantitative easing in November
and possibly negative rates next year, we doubt a deal will
trigger a major re-assessment of GBP prospects," they added.

But there are some hopes that a Brexit deal can be reached,
with Ireland's deputy Prime Minister and Northern Ireland
minister Brandon Lewis expressing optimism on Sunday.

Goldman Sachs FX strategists said that Brexit developments
were looking positive.

"Despite sterling's underperformance on Friday, we continue
to see a path for a sharply higher GBP/USD cross into year-end,"
they wrote in a note.

The EU's markets watchdog said on Monday banks and asset
managers based in the bloc should execute most of their share
trades inside the EU after full Brexit from January, in a step
set to fragment cross-border markets.

Elsewhere, news that a vaccine being developed by British
drugmaker AstraZeneca and the University of Oxford
produced an immune response in elderly and young people failed
to bolster market sentiment.

Britain's health minister said his central expectation was
for a vaccine to be rolled out for the first half of 2021.
(Reporting by Elizabeth Howcroft; editing by Emelia
Sithole-Matarise)

More News
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.